Xeris Pharmaceuticals Company Insiders
| XERS Stock | USD 4.82 0.26 5.70% |
Xeris Pharmaceuticals employs about 394 people. The company is managed by 13 executives with a total tenure of roughly 15 years, averaging almost 1.0 years of service per executive, having 30.31 employees per reported executive. Breaking down Xeris Pharmaceuticals' management performance can provide insight into the firm performance.
| Paul Edick CEO President CEO, Director |
| John Shannon President President COO |
Xeris |
Xeris Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.0533) % which means that it has lost $0.0533 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1716) %, meaning that it created substantial loss on money invested by shareholders. Xeris Pharmaceuticals' management efficiency ratios could be used to measure how well Xeris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Xeris Pharmaceuticals Workforce Comparison
Xeris Pharmaceuticals is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,205. Xeris Pharmaceuticals retains roughly 394 in number of employees claiming about 18% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13. Xeris Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xeris Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xeris Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Xeris Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anh Nguyen over two weeks ago Insider Trading | ||
Hecht Beth over two weeks ago Disposition of 14037 shares by Hecht Beth of Xeris Pharmaceuticals at 2.11 subject to Rule 16b-3 | ||
John Shannon over a month ago Acquisition by John Shannon of 800000 shares of Xeris Pharmaceuticals subject to Rule 16b-3 | ||
Johnson Kenneth Erland over a month ago Disposition of 25842 shares by Johnson Kenneth Erland of Xeris Pharmaceuticals at 3.56 subject to Rule 16b-3 | ||
Hecht Beth over two months ago Disposition of 320 shares by Hecht Beth of Xeris Pharmaceuticals at 3.61 subject to Rule 16b-3 | ||
John Shannon over three months ago Disposition of 15692 shares by John Shannon of Xeris Pharmaceuticals at 2.11 subject to Rule 16b-3 | ||
Steven Pieper over three months ago Disposition of 2640 shares by Steven Pieper of Xeris Pharmaceuticals at 1.55 subject to Rule 16b-3 | ||
Hecht Beth over six months ago Disposition of 5784 shares by Hecht Beth of Xeris Pharmaceuticals at 1.24 subject to Rule 16b-3 |
Xeris Pharmaceuticals Notable Stakeholders
A Xeris Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Xeris Pharmaceuticals often face trade-offs trying to please all of them. Xeris Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Xeris Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Paul Edick | President CEO, Director | Profile | |
| John Shannon | President COO | Profile | |
| Brian Conner | SVP Officer | Profile | |
| Anh Nguyen | Chief Officer | Profile | |
| PharmD D | Senior Affairs | Profile | |
| Beth JD | Chief Secretary | Profile | |
| Steven Pieper | Chief Officer | Profile | |
| Dr MBA | CoFounder Officer | Profile | |
| Paul JD | Senior Advisor | Profile | |
| Kendal Korte | Senior Resources | Profile | |
| Allison Wey | Senior Communications | Profile | |
| MD MBA | Chief Officer | Profile | |
| Kevin McCulloch | Chief Officer | Profile |
About Xeris Pharmaceuticals Management Performance
The success or failure of an entity such as Xeris Pharmaceuticals often depends on how effective the management is. Xeris Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Xeris management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Xeris management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Xeris Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people.
Please note, the imprecision that can be found in Xeris Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Xeris Pharmaceuticals. Check Xeris Pharmaceuticals' Beneish M Score to see the likelihood of Xeris Pharmaceuticals' management manipulating its earnings.
Xeris Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Xeris Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Xeris Pharmaceuticals within its industry.Xeris Pharmaceuticals Manpower Efficiency
Return on Xeris Pharmaceuticals Manpower
| Revenue Per Employee | 515.4K | |
| Revenue Per Executive | 15.6M | |
| Net Loss Per Employee | 139.2K | |
| Net Loss Per Executive | 4.2M | |
| Working Capital Per Employee | 170.6K | |
| Working Capital Per Executive | 5.2M |
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.